文章：

精准医疗时代下胆道癌靶向治疗现状

Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine

原文发布日期：22 February 2024

DOI: 10.3390/cancers16050879

类型: Article

开放获取: 是

英文摘要：

First-line chemotherapy has been established for advanced biliary tract cancer (BTC). However, few treatment options are available as second-line treatment. Advances in comprehensive genomic analysis revealed that nearly half of patients with BTC harbor targetable genetic alterations such as fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH), BRAF, human epidermal growth factor receptor 2 (HER2), microsatellite instability (MSI)-high, neurotrophic tropomyosin receptor kinase (NTRK), rearranged during transfection (RET), and poly (adenosine diphosphate-ribose) polymerase (PARP). This review summarizes currently available options in precision medicine and clinical trials for patients with advanced BTC.

摘要翻译： 

一线化疗方案已确立用于晚期胆道癌（BTC）的治疗。然而，作为二线治疗的选择却极为有限。综合基因组分析技术的进展显示，近半数BTC患者携带可靶向的基因变异，例如成纤维细胞生长因子受体（FGFR）、异柠檬酸脱氢酶（IDH）、BRAF、人类表皮生长因子受体2（HER2）、微卫星不稳定性高（MSI-H）、神经营养性原肌球蛋白受体激酶（NTRK）、转染重排（RET）以及聚腺苷二磷酸核糖聚合酶（PARP）。本综述总结了当前针对晚期BTC患者的精准医疗方案及临床试验进展。

原文链接：

Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision Medicine